Skip to main content
. 2014 May 8;111(21):7723–7728. doi: 10.1073/pnas.1318761111

Fig. 6.

Fig. 6.

TβRI kinase activity mediates the effect of hypomorphic ADAM17 on CEPC numbers in vivo. Mice were treated, or not, with 50 mg/kg of a pharmacological ADAM17 inhibitor, TMI-005, and/or 100mg/kg of an orally available TβRI kinase inhibitor, Ly2109761, before and during induction of angiogenesis, as described in the legend to Fig. 3. Mice were dosed twice a day with drug or vehicle, from one day before CarB implantation. Blood samples were collected before tumor implantation (0 h) and 24 h post implantation. CEPC and CEC numbers were assayed as described in Fig. 3. (A) CEC and (B) CEPC numbers, in response to inhibition of ADAM17 by TMI-005. Elevated induction of (C) CEPCs in congenic mice was neutralized by treatment with the TβRI kinase inhibitor, Ly2109761. Each time point reports the mean of four mice per experiment, and each experiment was replicated three times. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.